Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.52 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.52 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.52 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.52 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.52 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.52 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.52 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.52 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.52 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.52 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.52 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.51 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.49 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390410 | 0.98 | MAPT (0.59) | MAPTALDH1A1TDP1HPGDGABRP | |
| SCHEMBL193423 | 0.98 | MAPT (0.59) | MAPTALDH1A1TDP1HPGDGABRP | |
| Lithium Ion SCHEMBL31133341 | 0.96 | MAPT (0.57) | MAPTALDH1A1TDP1HPGDGABRP | |
| SCHEMBL28612277 | 0.96 | MAPT (0.57) | MAPTALDH1A1TDP1HPGDGABRP | |
| Pyridine SCHEMBL18550491 | 0.89 | MAPT (0.55) | MAPTALDH1A1TDP1HPGDGABRP | |
| SCHEMBL1892689 | 0.86 | GABRP (0.51) | MAPTALDH1A1TDP1HPGDGABRP | |
| SCHEMBL21819460 | 0.85 | MAPT (0.47) | MAPTALDH1A1TDP1HPGDGABRP | |
| SCHEMBL27293915 | 0.83 | MAPT (0.56) | MAPTALDH1A1TDP1HPGDNPC1 | |
| Hydrochloric Acid SCHEMBL3596374 | 0.82 | HTT (0.53) | MAPTALDH1A1TDP1HPGDNPC1 | |
| SCHEMBL31175233 | 0.82 | TDP1 (0.52) | MAPTALDH1A1TDP1HPGDGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-04-27 | — | — | US | disclosed |
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | LIPPA ARNOLD STAN (US) | 2021-11-04 | — | — | US | disclosed |
| US-20190112300-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3436021-A1 | COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDERS | RespireRx Pharmaceuticals Inc. (US) | 2019-02-06 | — | — | EP | disclosed |
| WO-2018009256-A1 | COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDERS | RESPIRERX PHARMACEUTICALS, INC. (US) | 2018-01-11 | — | — | WO | disclosed |
| US-9492440-B2 | Bicyclic amides for enhancing glutamatergic synaptic responses | RESPIRERX PHARMACEUTICALS INC (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2187888-B1 | BICYCLIC AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMA INC (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-2314295-A1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | Resverlogix, Inc (CA) | 2011-04-27 | — | — | EP | disclosed |
| US-20110003835-A1 | Methods for the treatment of respiratory depression | CORTEX PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| CN-101896183-A | Bicyclic amides for enhancing glutamatergic synaptic responses | CORTEX PHARMA INC | 2010-11-24 | — | — | CN | disclosed |
| US-20100286177-A1 | BICYCLIC AMIDES FOR THE TREATMENT OF RESPIRATORY DEPRESSION | CORTEX PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| CN-101862330-A | Bicyclic amide is used for the treatment of application in the medicament of respiration inhibition in preparation | CORTEX PHARMA INC | 2010-10-20 | — | — | CN | disclosed |
| EP-2233140-A1 | Bicyclic amides for enhancing glutamatergic synaptic responses | Biovail Laboratories International SRL (BB) | 2010-09-29 | — | — | EP | disclosed |
| EP-2187888-A2 | BICYCLIC AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009023126-A2 | BICYCLIC AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| CN-101365446-A | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery via implantable medical devices | RESVERLOGIX CORP (CA) | 2009-02-11 | — | — | CN | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | GRIN2A, GRIN2C, GRM2 | GABRP 101/4885GABRD 119/4885GABRA1 148/4885 |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | CHAT, NTRK2, GMFG | GABRP 206/4885GABRD 340/4885GABRA1 293/4885 |
| US-20110003835-A1 | Methods for the treatment of respiratory depression | BDNF, CHRNA10, CHRNA3 | GABRP 129/4885GABRD 174/4885GABRA1 104/4885 |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | GABRP 101/4885GABRD 119/4885GABRA1 148/4885 |
| US-20100286177-A1 | BICYCLIC AMIDES FOR THE TREATMENT OF RESPIRATORY DEPRESSION | BDNF, HCRTR2, CHRNA10 | GABRP 102/4885GABRD 162/4885GABRA1 127/4885 |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | VCAM1, ICAM1, TGFB1 | GABRP 3587/4885GABRD 3876/4885GABRA1 3737/4885 |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | GABRP 101/4885GABRD 119/4885GABRA1 148/4885 |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | GRIN2A, GRIN2C, NTRK2 | GABRP 107/4885GABRD 130/4885GABRA1 159/4885 |
| US-20190112300-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | GABRP 101/4885GABRD 119/4885GABRA1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.